Tapentadol Approved As Pain Reliever

摘要

Johnson & Johnson Pharmaceutical Research and Development LLC on November 21, 2008, announced that FDA approved the marketing of tapentadol immediate-release tablets for the relief of moderate to severe acute pain in adults.rnThe drug, FDA said, activates opioid receptors in the brain, spinal cord, and gastrointestinal tract and inhibits the reuptake of norepinephrine. Inhibition of norepinephrine uptake "possibly" produces an analgesic effect, the agency said.rnOfficial labeling for the new product has not been released by the company or FDA.rnThe company said tapentadol still needs a brand name and placement in a controlled-substance schedule.